Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Carisoprodol + aspirin + caffeine** is a combination drug consisting of three active ingredients: carisoprodol, a centrally acting skeletal muscle relaxant; aspirin, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and anti-inflammatory effects; and caffeine, a central nervous system stimulant sometimes included in analgesic combinations to enhance pain relief. Carisoprodol acts on the central nervous system to relieve muscle spasms primarily by blocking interneuronal activity in the spinal cord and reticular formation. Aspirin relieves pain and inflammation by inhibiting prostaglandin synthesis through irreversible inhibition of cyclooxygenase enzymes. Caffeine is thought to exert adjuvant analgesic effects, likely through adenosine receptor antagonism and vasoconstrictive properties, though its precise analgesic enhancement mechanism is not fully established. This combination is typically used for short-term relief of discomfort associated with acute, painful musculoskeletal conditions and is available by prescription only. The product is not intended as a substitute for rest, physical therapy, and other components of musculoskeletal management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carisoprodol + aspirin + caffeine.